Research programme: allergic rhinitis therapeutics - ENovate Biolife

Drug Profile

Research programme: allergic rhinitis therapeutics - ENovate Biolife

Alternative Names: E-AR-03; E-AR-07

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator ENovate Biolife
  • Class
  • Mechanism of Action Histamine release inhibitors; Immunoglobulin inhibitors; Interleukin 5 inhibitors; Leukotriene inhibitors; Mast cell stabilisers; NF-kappa B inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Allergic rhinitis

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Allergic-rhinitis in India
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top